Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Sep 07, 2023 9:17am
236 Views
Post# 35623714

Excessive visceral fat study

Excessive visceral fat study

 

This study seems to be close to being concluded as some centres have "completed" and some starting the recruitment as per the recent update

yesterday.

The purpose of it is among others to establish the relation between excessive visceral fat(not general obesity) and cardiovascular diseases in PLWH on various antivirals. It's a observational study so if the results clearly show a direct correlation between visceral and ectopic fat and serious co morbidities(heart diseases) it would be a useful tool to boost Egrifta's sales which reduces visceral fat. It is commonly known that obesity in both general population and subgroups such as HIV patients are linked to various common diseases but establishing a proven correlation between the real issue (the more problematic and more metabolic active visceral fat) to various serious conditions in subgroups such as PLWH is less acknowledged/understood by both doctors and their patients. The point is the purpose of this study and other ongoing studies about the problematic deeply stored fat, peripheral nerve damages, cognitive impairment etc. and the beneficial impact of Tesamorelin on those conditions some already proven others still under investigation is to increase the therapeutic potentials and value of the drug in various conditions each effecting patients who could benefit from additional treatment options.

History of Changes for Study: NCT05383456

<< Previous
Bullboard Posts
Next >>